Gastroenterology drug pipeline

IBD (Crohn's + UC), IBS, GERD, and other GI therapeutics.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. · 48 drugs
2. Xijing Hospital of Digestive Diseases · 12 drugs
3. Bausch Health Americas, Inc. · 11 drugs
4. National Taiwan University Hospital · 11 drugs
5. Takeda · 9 drugs
6. Abbott · 9 drugs
7. Norgine · 7 drugs
8. Sanofi · 6 drugs
9. Ain Shams University · 6 drugs
10. AstraZeneca · 6 drugs

Key drug classes

• Proton pump inhibitor (PPI) · 47
• Probiotic · 37
• Osmotic laxative · 37
• Proton pump inhibitor · 12
• 5-HT3 receptor antagonist · 12
• Anticholinergic agent · 8
• Pancreatic enzyme replacement therapy · 7
• Antacid · 7
• Potassium-competitive acid blocker (P-CAB) · 7
• 5-aminosalicylic acid (5-ASA) agent · 6
• Prostaglandin analog · 5
• NSAID + Proton pump inhibitor combination · 5
• Bowel preparation agent / Laxative combination · 4
• Bile acid · 4
• Rifamycin antibiotic · 4

Major diseases in this area

• crohns disease
• ulcerative colitis

Subscribe

Get gastroenterology approvals + PDUFA dates in your RSS reader:

• Gastroenterology RSS feed · Atom · JSON

Other therapeutic areas